Adial Pharmaceuticals ADILW 深 沪
交易中 05-20 10:27:40 美东时间
0.0009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 总市值 1.58万
- 52周最高 0.199
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 总股本 1750.35万
- 历史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending
Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending Overview U.S. addiction therapies developer's Q1 net loss narrowed from prior year on lower R&D spending Company highlighted regulatory changes that may speed AD04 approval and reduce development costs Adial set collaboration framework
05-11 20:38
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share
05-09 06:15
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
04-22 21:21
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an announcement. On April 7, 20...
04-10 05:37
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
U.S. Congress has introduced H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, to expand research and development of therapies for conditions affecting U.S. veterans, including Alcohol Use Disorder (AUD). The bill aligns with updated federal recovery standards, supporting non-abstinence-based treatments. Adial Pharmaceuticals, Inc. commends this bipartisan legislation, noting its potential to advance therapies like their inves...
03-24 13:07
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On Mar...
03-03 21:48
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
03-03 21:02
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program
Adial Pharmaceuticals ( ($ADIL) ) has shared an update. Adial Pharmaceuticals, ...
02-24 22:51
